The partnership will commercialize four nasal sprays with a combined Global IQVIA market size in excess of $400m
The acquisition would be by way of a share purchase agreement dated Dec. 26, 2022.
Showcased digital innovations: MyPKFit, SYNAPSE and Athena at the G20 Health Working Group Meeting
Everest and SPH Kyuan will work closely to promote import and channel distribution of XERAVA in China
The data highlight the three drug candidates' potential for clinical development and promising synergistic utilities in new indications
Acquisition positions Chiesi to expand patient access to approved treatments and advance efforts to develop new treatments for people living with rare diseases.
SVB Financial Group and its subsidiaries were involved in over $1.4 billion in total venture financing raised from 2010 to 2022 for drug development
The inspection included a comprehensive scrutiny of practices and procedures for reporting of adverse events of Lupin’s marketed products worldwide
Brexpiprazole Tablets, 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg, (RLD Rexulti) had estimated annual sales of US $1,575 million in the US (IQVIA MAT December 2022)
The common stock of Concert will no longer be listed for trading on the Nasdaq Global Market
Subscribe To Our Newsletter & Stay Updated
